News at a glance.

All resultsAd hoc announcement pursuant to Art. 53 LRPress release
  • Ad hoc announcement pursuant to Art. 53 LR, Tuesday, 7 March 2023

    The Galenica Group looks back on an extremely successful 2022 financial year. With an increase in sales of 4.7% to CHF 4,014.3 million and an adjusted¹ EBIT of CHF 200.8 million (-5.8%), Galenica achieved very good results. Excluding the extraordinary results in the previ-ous year from the COVID-19 initiatives (estimated at CHF 25 million) and the property sale at the headquarters in Bern (CHF 9.4 million), adjusted¹ EBIT growth amounted to a high 12.4%. The Board of Directors wants the shareholders to benefit from this success and will propose a divi-dend increase of 5% (CHF 2.20 per share) to the Annual General Meeting.

    After a normal seasonal flu season and numerous cases of the Omicron coronavirus variant had led to strong growth in the first half of 2022, business for the entire Group was also influenced in the second half of the year by the early onset of a heavy flu season. This had a particular im-pact on the Products & Brands sector, which grew at an above-average rate of 19.8%. In addi-tion, the extremely positive growth momentum of the previous year was continued in the 2022 financial year by the specialty pharmacy Mediservice (+12.9%) .

    Highlights of the 2022 financial year:

    • More than 121,000 customers made use of the services and advice offered in Galenica pharmacies, 60% more than in the previous year.
    • With a wide range of advice and services on offer, the pharmacy has further established it-self as the first point of contact for health issues.
    • The specialty pharmacy Mediservice made a significant contribution to the strong growth of the “Pharmacies at Home” sector and offered more than 60 main indications by the end of 2022, for a total of around 90 complex forms of therapy.
    • The linking of online and offline offerings gained further momentum, for example with online appointment bookings for pharmacy-based services via the Well health app.
    • Innovative offerings have further strengthened the home care sector: both existing and new B2B customers benefited from the joint venture Emeda and the offerings from Lifestage So-lutions, Bichsel and Medifilm.
    • Thanks to acquisitions and by obtaining distribution licences, Verfora further strengthened its leading position in the Swiss consumer healthcare market and expanded its portfolio through the distribution partnership with Boiron, particularly in the area of complementary medicine.
    • After a construction period of around 40 months, Galexis inaugurated its modernised dis-tribution centre in Lausanne-Ecublens in summer 2022.

    Key figures for the Galenica Group 2022:

    (in CHF million) 2022 2021 Change

    Net sales

    Products & Care segment




    Retail (B2C)




    Local Pharmacies




    Pharmacies at Home




    Professionals (B2B)




    Products & Brands




    Services for Professionals




    Logistics & IT segment








    Logistics & IT Services




    Corporate and eliminations



    Galenica Group




    EBIT adjusted1

    Products & Care segment1




    Logistics & IT segment1




    Corporate and eliminations



    Galenica Group1




    Net profit adjusted1




    1 Excluding the effects of IFRS 16 and IAS 19 (details of the adjusted key figures in the Annual Report 2022)

    Lieferung Apotheke
    Lieferung Apotheke
  • Press release, Tuesday, 31 January 2023

    The Galenica subsidiary Verfora will acquire 100% of Padma Ltd. at the end of January. Padma specialises in the manufacture and distribution of herbal formulations derived from Tibetan medicine. With the acquisition, Verfora is expanding its complementary medicine portfolio and expanding its range of reimbursable medicines.
  • Ad hoc announcement pursuant to Art. 53 LR, Wednesday, 18 January 2023

  • News, Tuesday, 8 November 2022

    In 2023, Galenica will grant all its employees a fixed cost-of-living adjustment. It is investing over CHF 14 million, thus increasing the payroll for its employees by a total of 3.1 per cent. Additional measures are being implemented for pharmacy staff to increase its attractiveness as an employer.

    All employees of the Galenica Group with a monthly salary of up to CHF 5,000 will receive a monthly salary increase of CHF 150. Employees with a monthly salary of over CHF 5,000 will receive CHF 100 per month (based on a 100% workload). By providing fixed and graduated cost-of-living adjustments, Galenica is sending a clear signal to its employees who are particularly affected by high inflation.

    In addition, Galenica is reaffirming its intention to address the shortage of skilled workers in the healthcare industry with additional measures for pharmacy staff.

    In pharmacies, entry-level salaries will be increased to CHF 4,100 to 4,500, depending on the region and canton. The recommendations of the cantonal pharmacists' associations will be used as a basis.
    The benchmark salaries for employees with work experience will be increased on the basis of the new entry-level salaries.

    Assuming a specific role by pharmacy specialists and thus taking on more responsibility – such as training apprentices – will in future be rewarded with position-related bonuses.

    The attractiveness as an employer is further increased with flat-rate mobility allowances, allowances for acting as a stand-in and team bonuses.

    Galenica is taking a further step towards covering the need for specialist staff in the future by providing a fixed cost-of-living adjustment for all employees as well as additional attractive measures for the pharmacy staff.

  • News, Wednesday, 21 September 2022

    Omni-channel – i.e. the link between online and offline – is a key element of the Galenica strategy. Contrary to earlier expectations, the Careproduct product range cannot be optimally integrated at Galenica. For this reason, Galenica is selling its subsidiary Careproduct to SAB Management Holding Ltd. and its owner Bruno Sauter, effective 20 September 2022.
  • News, Thursday, 8 September 2022

    After around 40 months of construction, Galexis opens the modernised distribution centre in Lausanne-Ecublens.

Subscribe to news

Media conferences and events


«Our communication focuses on the added value that we offer in the Galenica network for our customers and the Swiss healthcare system.»

Christina Hertig, Head of Corporate Communications

Media inquiries

Galenica Ltd.
Untermattweg 8
3027 Bern

Tel. +41 58 852 85 17